Literature DB >> 6602269

High dose systemic methotrexate-associated acute neurologic dysfunction.

R J Packer, R I Grossman, J B Belasco.   

Abstract

Two patients treated with high dose methotrexate otrexate with citrovorum rescue (HDMTX-CF) for osteogenic sarcoma developed the acute onset of neurologic deficits. Prior to the onset of symptoms, one child suffered brief episodes of altered consciousness. Both patients developed hemiparesis and then steadily improved over 72 hours. Laboratory evaluations disclosed normal coagulation parameters and nontoxic serum methotrexate levels at onset of symptoms. Computed tomography in one child disclosed a large low absorption abnormality. This patient represents the first reported case of positive radiologic findings associated with this syndrome. The two patients recovered completely and received further HDMTX-CF without sequelae. This condition may result from transient demyelination or embolic cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602269     DOI: 10.1002/mpo.2950110304

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  8 in total

1.  Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.

Authors:  M E Haykin; M Gorman; J van Hoff; R K Fulbright; J M Baehring
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity.

Authors:  Me Haykin; M Gorman; J van Hoff; Rk Fulbright; Jm Baehring
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 3.  Pharmacologic strategies for the treatment of meningeal malignancy.

Authors:  S M Blaney; D G Poplack
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Current pharmacological treatment approaches to central nervous system leukaemia.

Authors:  S M Blaney; F M Balis; D G Poplack
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

5.  Cerebral arterial disturbances in a transient encephalopathy induced by methotrexate.

Authors:  J Y Follezou; L Chauveinc; J M Guerin
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

6.  Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.

Authors:  April F Eichler; Tracy T Batchelor; John W Henson
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

7.  Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue.

Authors:  A Thyss; G Milano; M C Etienne; P Paquis; J L Roche; P Grelier; M Schneider
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

8.  The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series.

Authors:  Andrea Santangelo; Emanuele Bartolini; Giulia Nuzzi; Thomas Foiadelli; Alexandre Michev; Tommaso Mina; Irene Trambusti; Valeria Fichera; Alice Bonuccelli; Gabriele Massimetti; Diego G Peroni; Emanuela De Marco; Luca Coccoli; Laura Luti; Sayla Bernasconi; Margherita Nardi; Maria Cristina Menconi; Gabriella Casazza; Dario Pruna; Rosamaria Mura; Chiara Marra; Daniele Zama; Pasquale Striano; Duccio M Cordelli; Roberta Battini; Alessandro Orsini
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.